A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients

NCT00675545 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Hormone-Refractory Prostate Cancer

Interventions

DRUG: Docetaxel, Carboplatin

Sponsor

National University Hospital, Singapore